Vera eyes full approval for Trutakna in IgAN following positive readout

Data ReadoutpositiveTrutaknaPositive

AI Analysis

Summary

Vera Therapeutics announced positive two-year data for Trutakna demonstrating stabilization of kidney function in IgAN patients, supporting a planned FDA submission for full approval of the recently approved drug.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Two-year data showed Trutakna stabilized kidney function in patients with IgAN

Importance:7/10

Sentiment:

0.70

kidney diseaseautoimmuneFDA submission plannedfull approval pathwayIgAN

Related Companies

$VERA

Read the original article

Published by Endpoints News on September 15, 2026 10:30 AM

Read Original